-
Bio Blast Gains 9%, Company Will Present Final Phase 2 Trial Data At Industry Conference
Friday, April 15, 2016 - 8:13am | 176Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN) were trading higher by more than 9 percent early Friday morning after the company announced it will present final data from a Phase 2 clinical study at the American Academy of Neurology (AAN) 2016 Annual Meeting. Bio Blast Pharma is a clinical-stage...